Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
IntroductionBreast cancer is the most common type of cancer affecting women in Europe. Advanced breast cancer (ABC) poses a significant therapeutic challenge, and therefore, timely access to treatment is crucial. The aim of the present study was to evaluate the treatment patterns and patients'...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1073733/full |
| _version_ | 1811160818950078464 |
|---|---|
| author | Stephanie Karanyotova Branimira Topova Elina Petrova Peter Doychev Eliana Kapitanska Guenka Petrova Zornitsa Mitkova Maria Dimitrova |
| author_facet | Stephanie Karanyotova Branimira Topova Elina Petrova Peter Doychev Eliana Kapitanska Guenka Petrova Zornitsa Mitkova Maria Dimitrova |
| author_sort | Stephanie Karanyotova |
| collection | DOAJ |
| description | IntroductionBreast cancer is the most common type of cancer affecting women in Europe. Advanced breast cancer (ABC) poses a significant therapeutic challenge, and therefore, timely access to treatment is crucial. The aim of the present study was to evaluate the treatment patterns and patients' access to new therapies for ABC in Bulgaria.MethodsWe conducted a retrospective study in the period 2008–2021. Based on the European Medicines Agency (EMA) database, we analyzed a number of medicinal products with marketing authorization for ABC in the last 13 years. Time to market access was evaluated as the degree of availability, which is measured by the number of medicines that are available to patients (availability index, AI), and the average time elapsed between obtaining a marketing authorization and time to inclusion in the Positive Drug List. Data were analyzed through descriptive statistics via Microsoft Excel version 10.ResultsThe average time to access was 564 days for targeted therapy. The availability and compliance index for chemotherapy and hormonal therapy in advanced breast cancer was 1, while the average AI for targeted therapy was 0.67. Patient access to targeted oncology therapy of ABC is above average for Europe and takes 1–2 years.ConclusionFaster access is more evident for biosimilars. National regulatory requirements for pricing and reimbursement have a major impact on market access. |
| first_indexed | 2024-04-10T06:04:02Z |
| format | Article |
| id | doaj.art-848387f480974804b08b61e52816a091 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-10T06:04:02Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-848387f480974804b08b61e52816a0912023-03-03T04:51:34ZengFrontiers Media S.A.Frontiers in Public Health2296-25652023-03-011110.3389/fpubh.2023.10737331073733Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in BulgariaStephanie KaranyotovaBranimira TopovaElina PetrovaPeter DoychevEliana KapitanskaGuenka PetrovaZornitsa MitkovaMaria DimitrovaIntroductionBreast cancer is the most common type of cancer affecting women in Europe. Advanced breast cancer (ABC) poses a significant therapeutic challenge, and therefore, timely access to treatment is crucial. The aim of the present study was to evaluate the treatment patterns and patients' access to new therapies for ABC in Bulgaria.MethodsWe conducted a retrospective study in the period 2008–2021. Based on the European Medicines Agency (EMA) database, we analyzed a number of medicinal products with marketing authorization for ABC in the last 13 years. Time to market access was evaluated as the degree of availability, which is measured by the number of medicines that are available to patients (availability index, AI), and the average time elapsed between obtaining a marketing authorization and time to inclusion in the Positive Drug List. Data were analyzed through descriptive statistics via Microsoft Excel version 10.ResultsThe average time to access was 564 days for targeted therapy. The availability and compliance index for chemotherapy and hormonal therapy in advanced breast cancer was 1, while the average AI for targeted therapy was 0.67. Patient access to targeted oncology therapy of ABC is above average for Europe and takes 1–2 years.ConclusionFaster access is more evident for biosimilars. National regulatory requirements for pricing and reimbursement have a major impact on market access.https://www.frontiersin.org/articles/10.3389/fpubh.2023.1073733/fulladvanced breast cancerpatient accesstargeted therapyavailability indexcompliance index |
| spellingShingle | Stephanie Karanyotova Branimira Topova Elina Petrova Peter Doychev Eliana Kapitanska Guenka Petrova Zornitsa Mitkova Maria Dimitrova Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria Frontiers in Public Health advanced breast cancer patient access targeted therapy availability index compliance index |
| title | Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria |
| title_full | Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria |
| title_fullStr | Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria |
| title_full_unstemmed | Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria |
| title_short | Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria |
| title_sort | treatment patterns adherence to international guidelines and financial mechanisms of the market access of advanced breast cancer therapy in bulgaria |
| topic | advanced breast cancer patient access targeted therapy availability index compliance index |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1073733/full |
| work_keys_str_mv | AT stephaniekaranyotova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT branimiratopova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT elinapetrova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT peterdoychev treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT elianakapitanska treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT guenkapetrova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT zornitsamitkova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria AT mariadimitrova treatmentpatternsadherencetointernationalguidelinesandfinancialmechanismsofthemarketaccessofadvancedbreastcancertherapyinbulgaria |